Immune Cell Regeneration and Gaining Strength to Attack Multiple Myeloma Cancer
DOI:
https://doi.org/10.47611/jsrhs.v12i4.5893Keywords:
Multiple Myeloma, Immunotherapy, CAR - T Cell Therapy, Monoclonal Antibodies, Stem Cell Regeneration, Immune SystemAbstract
Multiple Myeloma is a rare cancer that primarily affects plasma cells that differentiate into white blood cells (which have important roles in the immune system such as fighting off infections and diseases). Once these plasma cells are transformed into cancerous cells that invade the space of the bone marrow, there is a prevention of the existence of future healthy immune cells that help the human body systems. Due to these viscous effects of the Multiple Myeloma, the blood cell count decreases and patients’ immunity lowers. The weakened immune systems of patients can attack the components of the treatments which leads to the wastage of money, time, and energy of the patients and the medical professionals. With the current research, patients can gain back strength and improve their immune systems. By the usage of the regeneration of stem cells, immunotherapy to increase the resistance of immune cells against the cancer, Chimeric Antigen Receptor T Cell therapy (or CAR-T Cell Therapy), and monoclonal antibody therapies, patients can gain back strength and improve their immune systems in a way that attacks Multiple Myeloma. Yet there is still growth for improvement, since the process of patients receiving treatments must be repeated multiple times due to the intensity and persistence of this cancer. By studying and researching the effects of Multiple Myeloma on immune cells, this paper’s goal is to find ways to improve current treatments and how to regenerate stronger and healthier immune cells which can resist and potentially defeat Multiple Myeloma Cancer.
Downloads
References or Bibliography
American Cancer Society. (2023). Cancer Facts & Figures 2023. Atlanta, Ga: American Cancer Society. Retrieved from: https://www.cancer.org/content/dam/CRC/PDF/Public/8738.00.pdf
Atanackovic, D., Steinbach, M., Radhakrishnan, S. V., & Luetkens, T. (2016). Immunotherapies targeting CD38 in Multiple Myeloma. OncoImmunology, 5(11), e1217374. https://doi.org/10.1080/2162402x.2016.1217374
Balasa, B., Yun, R., Belmar, N. A., Fox, M., Chao, D. T., Robbins, M., Starling, G. C., & Rice, A. (2014). Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways. Cancer Immunology, Immunotherapy, 64(1), 61–73. https://doi.org/10.1007/s00262-014-1610-3
CAR T cells: Engineering immune cells to treat cancer. (2022). National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/research/car-t-cells#:~:text=They%20are%20made%20by%20collecting,the%20surface%20of%20cancer%20cells.
Dulak, J., Szade, K., Szade, A., Nowak, W., & Jozkowicz, A. (2015). Adult stem cells: hopes and hypes of regenerative medicine. Acta Biochimica Polonica, 62(3), 329–337. https://doi.org/10.18388/abp.2015_1023
Howlader, N., Noone AM., Krapcho M., Miller D., Bishop K., Kosary CL., Yu M., Ruhl J., Tatalovich Z., Mariotto A., Lewis DR., Chen HS., Feuer EJ., Cronin KA. (2017). SEER Cancer Statistics Review, 1975-2014, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2014/, based on November 2016 SEER data submission.
Immunotherapy for cancer. (2019). National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/types/immunotherapy
Magen, H., & Muchtar, E. (2016). Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment. Therapeutic Advances in Hematology, 7(4), 187–195. https://doi.org/10.1177/2040620716652862
McCluskey, K. (2022). Immunotherapy vs. Chemotherapy: What’s the Difference? Cancer Research Institute. https://www.cancerresearch.org/blog/june-2016/difference-cancer-immunotherapy-and-chemotherapy
Monoclonal antibodies. (2019). National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/monoclonal-antibodies
Professional, C. C. M. (2022). Multiple myeloma. Cleveland Clinic. https://my.clevelandclinic.org/health/articles/6178-multiple-myeloma
Side effects of immunotherapy. (2023). National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/side-effects
Stem cell transplants in cancer treatment. (2015). National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/types/stem-cell-transplant#:~:text=Stem%20cell%20transplants%20are%20procedures,different%20types%20of%20blood%20cells.
Sterner, R. C., & Sterner, R. M. (2021). CAR-T cell therapy: current limitations and potential strategies. Blood Cancer Journal, 11(4). https://doi.org/10.1038/s41408-021-00459-7
The innate and adaptive immune systems. (2020). National Library of Medicine. Retrieved August 5, 2023, from https://www.ncbi.nlm.nih.gov/books/NBK279396/#:~:text=The%20innate%20immune%20system%20is,the%20%22nonspecific%22%20immune%20system.
understanding multiple myeloma. (2013). [Slide show]. Leukemia & Lymphoma Society. https://www.lls.org/sites/default/files/chapters/wi/Pdf/WI-Understanding%20Multiple%20Myeloma%20%20Lab%20Values%20-%20Benjamin%20Parsons%20MD.pdf
Website, N. (2022, December 16). What happens. nhs.uk. https://www.nhs.uk/conditions/stem-cell-transplant/what-happens/#:~:text=from%20cord%20blood%20%E2%80%93%20where%20donated,NHS%20Blood%20and%20Transplant%20website
What is a stem cell or bone marrow transplant? (2022). Stem Cell and Bone Marrow Transplants | Cancer Research UK. https://www.cancerresearchuk.org/about-cancer/treatment/bone-marrow-stem-cell-transplants/what-is
Whitbourne, K. (2017). Should you bank your baby’s cord blood? WebMD. https://www.webmd.com/baby/should-you-bank-your-babys-cord-blood
Why People with Cancer Are More Likely to Get Infections. (2020). American Cancer Society. https://www.cancer.org/cancer/managing-cancer/side-effects/low-blood-counts/infections/why-people-with-cancer-are-at-risk.html
Published
How to Cite
Issue
Section
Copyright (c) 2023 Jessica Joseph; Mrs. Jothsna Kethar, Dr. Rajagopal Appavu, Ph.D
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright holder(s) granted JSR a perpetual, non-exclusive license to distriute & display this article.
